1. What is the projected Compound Annual Growth Rate (CAGR) of the U.S. Contraceptive Drugs Market?
The projected CAGR is approximately 6.8%.
U.S. Contraceptive Drugs MarketU.S. Contraceptive Drugs Market Strategic Roadmap: Analysis and Forecasts 2025-2033
U.S. Contraceptive Drugs Market by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channels, Public Channels & NGOs, Others), by Forecast 2025-2033
Base Year: 2024
180 Pages
U.S. Contraceptive Drugs Market Strategic Roadmap: Analysis and Forecasts 2025-2033
U.S. Contraceptive Drugs Market Strategic Roadmap: Analysis and Forecasts 2025-2033
Key Insights
The U.S. Contraceptive Drugs Market size was valued at USD 6.25 USD Billion in 2023 and is projected to reach USD 9.91 USD Billion by 2032, exhibiting a CAGR of 6.8 % during the forecast period. Oral contraceptive pills are pharmaceutical substances that are used for avoiding conception by influencing ovulation with one of them or modifying cervical mucus and sperm utilization. COCs, POPs, contraceptive patches, implants, and IUDs which don't make any sub-category, can be stated as different types of them. Such medications have a number of benefits that are given by their specific nature. Among them are high effectiveness, convenience of use, and reversible action at the moment of sudden cessation. As contraceptive methods and regular menstruation are widely used, they also address reproductive conditions which include PCOS and endometriosis. In the U.S. , market trends show a rising interest in the LARCs (long-acting reversible contraceptives) which is a good measure of their efficiency and ease of use, and women and men who want to avoid taking hormonal birth control because of side effects prefer non-hormonal methods, research shows.
U.S. Contraceptive Drugs Trends
- Rising awareness of family planning and reproductive health
- Increasing demand for long-acting reversible contraceptives (LARCs)
- Growing preference for non-hormonal contraceptives
- Technological advancements in drug delivery systems
Driving Forces: What's Propelling the U.S. Contraceptive Drugs Market
- Government initiatives to promote family planning
- Increasing health insurance coverage for contraception
- Growing female workforce participation
- Expanding awareness of contraception options for adolescents
Challenges and Restraints in the U.S. Contraceptive Drugs Market
- Lack of access to affordable contraception
- Religious and cultural barriers
- Side effects associated with hormonal contraceptives
- Limited availability of non-hormonal contraceptives
Emerging Trends in U.S. Contraceptive Drugs
- Development of next-generation LARCs with lower side effects
- Integration of artificial intelligence in contraception management
- Telemedicine-based contraception access
- Personalized contraception options based on genetic testing
Growth Catalysts in the U.S. Contraceptive Drugs Industry
- Rising investment in research and development of new contraceptives
- Government funding for family planning programs
- Partnerships between pharmaceutical companies and non-profit organizations
- Educational campaigns to promote contraception awareness
Market Segmentation: U.S. Contraceptive Drugs Analysis
Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Clinics
- Online Channels
- Public Channels & NGOs
- Others
Type:
- Hormonal
- Birth control pills
- Contraceptive patches
- Contraceptive injections
- Contraceptive implants
- Non-hormonal
- Condoms
- Diaphragms
- IUDs
Leading Players in the U.S. Contraceptive Drugs Market
- Agile Therapeutics (U.S.)
- Johnson & Johnson Services, Inc. (U.S.)
- AbbVie Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Viatris Inc. (U.S.)
- Amneal Pharmaceuticals, Inc. (U.S.)
- Bayer AG (Germany)
Significant Developments in the U.S. Contraceptive Drugs Sector
- August 2023: Lupin received U.S. FDA approval for a generic equivalent of Wyeth Pharmaceuticals LLC's Lo/Ovral-28 tablets, known as Turqoz.
- July 2023: Opill (norgestrel) tablets received U.S. FDA approval. This marks the first nonprescription oral contraceptive for daily use.
- February 2021: Amneal Pharmaceuticals, Inc. received U.S. FDA approval for its Abbreviated New Drug Application for Zafemy, the generic version of Ortho Evra, aimed at preventing pregnancy in women in February 2021.
Comprehensive Coverage U.S. Contraceptive Drugs Market Report
Enhanced Content:Our updated report provides a comprehensive analysis of the U.S. Contraceptive Drugs Market, including:
- Detailed Market Overview: Historical and forecasted market size, market share, and growth trends.
- Competitive Landscape: Profiles of key players, their market share, product portfolio, and competitive strategies.
- Product Segmentation: Market size and growth projections for different types of contraceptive drugs, including oral contraceptives, injectables, implants, and emergency contraceptives.
- Distribution Channels: Analysis of the distribution channels used for contraceptive drugs, including pharmacies, clinics, and online retailers.
- Regulatory Landscape: Overview of the regulatory framework governing the development, approval, and marketing of contraceptive drugs.
- DROC Analysis: In-depth analysis of drug resistance, over-the-counter (OTC) switch, and competitive dynamics in the contraceptive drugs market.
- Pricing Analysis: Comparative analysis of drug prices, discounts, and rebates across different channels.
- Import and Export Analysis: Data on the import and export of contraceptive drugs, including destinations and sources.
- Patent/Trademark Analysis: Review of patents and trademarks held by key players in the market.
Our report provides valuable insights for manufacturers, distributors, healthcare providers, and policymakers seeking to navigate the evolving contraceptive drugs market in the United States.
U.S. Contraceptive Drugs Market REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2019-2033 |
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025-2033 |
| Historical Period | 2019-2024 |
| Growth Rate | CAGR of 6.8% from 2019-2033 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Introduction of Cost-effective Manufacturing Processes to Drive Market Growth
- 3.3. Market Restrains
- 3.3.1. Side Effects Associated with Usage of Contraceptive Drugs to Impede Market Growth
- 3.4. Market Trends
- 3.4.1. Increasing Number of Hospitals and ASCs Identified as Significant Market Trend
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. U.S. Contraceptive Drugs Market Analysis, Insights and Forecast, 2019-2031
- 5.1. Market Analysis, Insights and Forecast - by Distribution Channel
- 5.1.1. Hospital Pharmacy
- 5.1.2. Retail Pharmacy
- 5.1.3. Clinics
- 5.1.4. Online Channels
- 5.1.5. Public Channels & NGOs
- 5.1.6. Others
- 5.2. Market Analysis, Insights and Forecast - by Region
- 5.2.1.
- 5.1. Market Analysis, Insights and Forecast - by Distribution Channel
- 6. Northeast U.S. Contraceptive Drugs Market Analysis, Insights and Forecast, 2019-2031
- 7. Southeast U.S. Contraceptive Drugs Market Analysis, Insights and Forecast, 2019-2031
- 8. Midwest U.S. Contraceptive Drugs Market Analysis, Insights and Forecast, 2019-2031
- 9. Southwest U.S. Contraceptive Drugs Market Analysis, Insights and Forecast, 2019-2031
- 10. West U.S. Contraceptive Drugs Market Analysis, Insights and Forecast, 2019-2031
- 11. Competitive Analysis
- 11.1. Market Share Analysis 2024
- 11.2. Company Profiles
- 11.2.1 Agile Therapeutics (U.S.)
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 Johnson & Johnson Services Inc. (U.S.)
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 AbbVie Inc. (U.S.)
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 Pfizer Inc. (U.S.)
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.5 Teva Pharmaceutical Industries Ltd. (Israel)
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Financials (Based on Availability)
- 11.2.6 Viatris Inc. (U.S.)
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Financials (Based on Availability)
- 11.2.7 Amneal Pharmaceuticals Inc. (U.S.)
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Financials (Based on Availability)
- 11.2.8 Bayer AG (Germany)
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Financials (Based on Availability)
- 11.2.1 Agile Therapeutics (U.S.)
List of Figures
- Figure 1: U.S. Contraceptive Drugs Market Revenue Breakdown (USD Billion, %) by Product 2024 & 2032
- Figure 2: U.S. Contraceptive Drugs Market Share (%) by Company 2024
List of Tables
- Table 1: U.S. Contraceptive Drugs Market Revenue USD Billion Forecast, by Region 2019 & 2032
- Table 2: U.S. Contraceptive Drugs Market Volume K Units Forecast, by Region 2019 & 2032
- Table 3: U.S. Contraceptive Drugs Market Revenue USD Billion Forecast, by Distribution Channel 2019 & 2032
- Table 4: U.S. Contraceptive Drugs Market Volume K Units Forecast, by Distribution Channel 2019 & 2032
- Table 5: U.S. Contraceptive Drugs Market Revenue USD Billion Forecast, by Region 2019 & 2032
- Table 6: U.S. Contraceptive Drugs Market Volume K Units Forecast, by Region 2019 & 2032
- Table 7: U.S. Contraceptive Drugs Market Revenue USD Billion Forecast, by Country 2019 & 2032
- Table 8: U.S. Contraceptive Drugs Market Volume K Units Forecast, by Country 2019 & 2032
- Table 9: Northeast U.S. Contraceptive Drugs Market Revenue (USD Billion) Forecast, by Application 2019 & 2032
- Table 10: Northeast U.S. Contraceptive Drugs Market Volume (K Units) Forecast, by Application 2019 & 2032
- Table 11: Southeast U.S. Contraceptive Drugs Market Revenue (USD Billion) Forecast, by Application 2019 & 2032
- Table 12: Southeast U.S. Contraceptive Drugs Market Volume (K Units) Forecast, by Application 2019 & 2032
- Table 13: Midwest U.S. Contraceptive Drugs Market Revenue (USD Billion) Forecast, by Application 2019 & 2032
- Table 14: Midwest U.S. Contraceptive Drugs Market Volume (K Units) Forecast, by Application 2019 & 2032
- Table 15: Southwest U.S. Contraceptive Drugs Market Revenue (USD Billion) Forecast, by Application 2019 & 2032
- Table 16: Southwest U.S. Contraceptive Drugs Market Volume (K Units) Forecast, by Application 2019 & 2032
- Table 17: West U.S. Contraceptive Drugs Market Revenue (USD Billion) Forecast, by Application 2019 & 2032
- Table 18: West U.S. Contraceptive Drugs Market Volume (K Units) Forecast, by Application 2019 & 2032
- Table 19: U.S. Contraceptive Drugs Market Revenue USD Billion Forecast, by Distribution Channel 2019 & 2032
- Table 20: U.S. Contraceptive Drugs Market Volume K Units Forecast, by Distribution Channel 2019 & 2032
- Table 21: U.S. Contraceptive Drugs Market Revenue USD Billion Forecast, by Country 2019 & 2032
- Table 22: U.S. Contraceptive Drugs Market Volume K Units Forecast, by Country 2019 & 2032
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segments, product, and application.
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
Additionally, after gathering mixed and scattered data from a wide range of sources, data is triangulated and correlated to come up with estimated figures which are further validated through primary mediums or industry experts, opinion leaders.
Frequently Asked Questions
2. Which companies are prominent players in the U.S. Contraceptive Drugs Market?
Key companies in the market include Agile Therapeutics (U.S.), Johnson & Johnson Services, Inc. (U.S.), AbbVie Inc. (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Viatris Inc. (U.S.), Amneal Pharmaceuticals, Inc. (U.S.), Bayer AG (Germany).
3. What are the main segments of the U.S. Contraceptive Drugs Market?
The market segments include Distribution Channel.
4. Can you provide details about the market size?
The market size is estimated to be USD 6.25 USD Billion as of 2022.
5. What are some drivers contributing to market growth?
Introduction of Cost-effective Manufacturing Processes to Drive Market Growth.
6. What are the notable trends driving market growth?
Increasing Number of Hospitals and ASCs Identified as Significant Market Trend.
7. Are there any restraints impacting market growth?
Side Effects Associated with Usage of Contraceptive Drugs to Impede Market Growth.
8. Can you provide examples of recent developments in the market?
August 2023 – Lupin received U.S. FDA approval for a generic equivalent of Wyeth Pharmaceuticals LLC's Lo/Ovral-28 tablets, known as Turqoz.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 2850, USD 3850, and USD 4850 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in USD Billion and volume, measured in K Units.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "U.S. Contraceptive Drugs Market," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the U.S. Contraceptive Drugs Market report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the U.S. Contraceptive Drugs Market?
To stay informed about further developments, trends, and reports in the U.S. Contraceptive Drugs Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Related Reports
About Market Research Forecast
MR Forecast provides premium market intelligence on deep technologies that can cause a high level of disruption in the market within the next few years. When it comes to doing market viability analyses for technologies at very early phases of development, MR Forecast is second to none. What sets us apart is our set of market estimates based on secondary research data, which in turn gets validated through primary research by key companies in the target market and other stakeholders. It only covers technologies pertaining to Healthcare, IT, big data analysis, block chain technology, Artificial Intelligence (AI), Machine Learning (ML), Internet of Things (IoT), Energy & Power, Automobile, Agriculture, Electronics, Chemical & Materials, Machinery & Equipment's, Consumer Goods, and many others at MR Forecast. Market: The market section introduces the industry to readers, including an overview, business dynamics, competitive benchmarking, and firms' profiles. This enables readers to make decisions on market entry, expansion, and exit in certain nations, regions, or worldwide. Application: We give painstaking attention to the study of every product and technology, along with its use case and user categories, under our research solutions. From here on, the process delivers accurate market estimates and forecasts apart from the best and most meaningful insights.
Products generically come under this phrase and may imply any number of goods, components, materials, technology, or any combination thereof. Any business that wants to push an innovative agenda needs data on product definitions, pricing analysis, benchmarking and roadmaps on technology, demand analysis, and patents. Our research papers contain all that and much more in a depth that makes them incredibly actionable. Products broadly encompass a wide range of goods, components, materials, technologies, or any combination thereof. For businesses aiming to advance an innovative agenda, access to comprehensive data on product definitions, pricing analysis, benchmarking, technological roadmaps, demand analysis, and patents is essential. Our research papers provide in-depth insights into these areas and more, equipping organizations with actionable information that can drive strategic decision-making and enhance competitive positioning in the market.